Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design

Bipolar Disorders

Volumn 4, Issue 6, 2002, Pages 412-417

  Hummel, Barbara ^a   Walden, Joerg ^b   Stampfer, Robert ^a   Dittmann, Sandra ^a   Amann, Benedikt ^a   Sterr, Andrea ^a   Schaefer, Martin ^a   Frye, Mark A ^c   Grunze, Heinz ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulsants; Bipolar disorder mania; Oxcarbazepine

Indexed keywords

OXCARBAZEPINE; PHENYTOIN;

ADULT; ARTICLE; ATAXIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; MANIA; METHODOLOGY; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SWEATING; SYMPTOM; TITRIMETRY; TREATMENT OUTCOME; VERTIGO;

ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0347927722     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2002.02228.x     Document Type: Article

References (29)

1. Emrich HM. Experiences with oxcarbazepine in acute mania. In: Modigh K, Robak OH, Vestergaard P, ed. Anticonvulsants in Psychiatry. Petersfield: Wrightson Biomedical Publishing Ltd, 1994: 23-35.
2. Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994; 35: 1217-1220.
3. Larkin JG, McKee PJ, Forrest G et al. Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991; 31: 65-71.
4. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR. Oxcarbazepine. preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35 (Suppl. 5): S47-S50.
5. Calabresi P, De Murtas M, Stefani A et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36: 990-996.
6. McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35 (Suppl. 3): S5-S9.
7. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995; 45: 1907-1913.
8. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 (Suppl. 3): S14-S19.
9. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994; 35 (Suppl. 3): S23-S25.
10. Gram L. Clinical experience with oxcarbazepine. Epilepsia 1994; 35 (Suppl. 3): S21-S22.
11. Elwes RD, Binnie CD. Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin Pharmacokinet 1996; 30: 403-415.
12. Jung H, Noguez A, Mayet L, Fuentes I, Gonzalez-Esquivel DF. The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Dispos 1997; 18: 17-23.
13. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 (Suppl. 3): S10-S13.
14. Rouan MC, Lecaillon JB, Godbillon J et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-167.
15. Friis ML, Kristensen O, Boas J et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-227.
16. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2: 159-175.
17. Lenzi A, Lazzerini F, Grossi E, Massimetti G, Placidi GF. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986; 14: 78-84.
18. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198-204.
19. Okuma T, Inanaga K, Otsuki S et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharmacology 1979; 66: 211-217.
20. Okuma T, Yamashita I, Takahashi R et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23: 143-150.
21. Grant SM, Faulds D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 1992; 43: 873-888.
22. Emrich HM, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 1985; 8: 243-250.
23. Emrich HE. Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5 (Suppl. 1): 83-88.
24. Müller AA, Stoll K-D. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: studies in Germany. In: Emrich HM, Okuma T, Muller AA ed. Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science Ltd., 1984: 139-147.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association, 1994.
26. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
27. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
28. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
29. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181-188.